AbbVie Inc. (ABBV) |
|
144.95 0.11 (0.08%)
|
02-03 14:57 |
|
Open: |
145.92 |
Pre. Close: |
144.84 |
|
High:
|
146.78 |
Low:
|
144.86 |
|
Volume:
|
3,211,485 |
Market Cap:
|
256,341(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 2:44:48 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 185.34 One year: 196.35 |
| Support: |
Support1: 143.44 Support2: 119.34 |
| Resistance: |
Resistance1: 158.68 Resistance2: 168.11 |
| Pivot: |
148.1  |
| Moving Average: |
MA(5): 145.99 MA(20): 150.94
MA(100): 151.48  MA(250): 150.33 |
| MACD: |
MACD(12,26): -3.7 Signal(9): -3.4 |
| Stochastic oscillator: |
%K(14,3): 13.6 %D(3): 13.4 |
| RSI: |
RSI(14): 30.4 |
| 52-week: |
High: 175.91 Low: 134.08 |
| Average Vol(K): |
3-Month: 5,397 (K) 10-Days: 5,009 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed above bottom band by 19.2%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
146.21 - 147.04 |
147.04 - 147.94 |
|
Low:
|
141.1 - 142.02 |
142.02 - 143.03 |
|
Close:
|
143.09 - 144.7 |
144.7 - 146.46 |
|
Company Description |
|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
Headline News |
Fri, 03 Feb 2023
Should You Buy AbbVie Inc (ABBV) Stock on Friday? - InvestorsObserver
Fri, 03 Feb 2023
ABBV: The 5 Best Stocks to Invest $1,000 in Right Now - StockNews.com
Fri, 03 Feb 2023
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You ... - Nasdaq
Fri, 03 Feb 2023
Is AbbVie (ABBV) an Attractive Investment Option? - Yahoo Finance
Thu, 02 Feb 2023
ABBV March 24th Options Begin Trading - Nasdaq
Thu, 02 Feb 2023
ABBV: These 3 Dividend Stocks Are Worth Investing In - StockNews.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
1,770 (M) |
| Shares Float |
1,770 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
70.8 (%) |
|
Shares Short
|
11,960 (K) |
|
Shares Short P.Month
|
13,580 (K) |
Stock Financials |
|
EPS
|
7.5 |
|
EPS Est Next Qtl
|
1.44 |
|
EPS Est This Year
|
5.53 |
|
EPS Est Next Year
|
6.55 |
|
Book Value (p.s.)
|
9.03 |
|
Profit Margin (%)
|
23.1 |
|
Operating Margin (%)
|
37.2 |
|
Return on Assets (ttm)
|
9.2 |
|
Return on Equity (ttm)
|
90.6 |
|
Qtrly Rev. Growth
|
3.2 |
|
Gross Profit (p.s.)
|
21.96 |
|
Sales Per Share
|
32.66 |
|
EBITDA (p.s.)
|
16.83 |
|
Qtrly Earnings Growth
|
24.2 |
|
Operating Cash Flow
|
22,590 (M) |
|
Levered Free Cash Flow
|
20,200 (M) |
Stock Valuations |
|
PE Ratio
|
19.34 |
|
PEG Ratio
|
-3.6 |
|
Price to Book value
|
16.05 |
|
Price to Sales
|
4.44 |
|
Price to Cash Flow
|
11.36 |
Stock Dividends |
|
Dividend
|
1.48 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1% |
|
Dividend Pay Date
|
2022-02-14 |
|
Ex-Dividend Date
|
2022-01-12 |
|
Your Ad Here
|
|
